Professor Robert Clarke
- BEST-D: Biochemical Efficacy and Safety Trial of Vitamin D
- China Kadoorie Biobank
- HPS: Heart Protection Study
- PROCARDIS Sibling-pair Studies of Genetic Determinants of MI
- Re-survey and Follow-up of 1970 Whitehall Study
- SEARCH: Study of the Effectiveness of Additional Reductions in Cholesterol and Homocysteine
- Development of cardiovascular risk prediction model for Chinese adults
MD, MSc, DCH
Emeritus Professor of Epidemiology and Public Health Medicine
- Clinical Trial Service Unit and Epidemiological Studies Unit
Robert Clarke is an Emeritus Professor of Epidemiology and Public Health Medicine at the Clinical Trial Service Unit and Epidemiological Studies Unit (CTSU), Honorary Consultant in Public Health Medicine and Scientific Director of the MSc in Global Health Science and Epidemiology. He qualified in clinical medicine in Ireland and worked for five years in internal medicine and four years in cardiology. After two years in clinical pharmacology at Vanderbilt University, Nashville, USA, he joined CTSU in 1991 and specialised in cardiovascular epidemiology.
His main research interests are to understand the importance of classical and novel risk factors for cardiovascular diseases. He worked on analyses of observational studies and trials in the UK and meta-analyses of international consortia of observational studies, genome-wide association studies and randomised trials for heart disease and stroke. Over the last decade, his research work has focussed on understanding the causes of stroke and heart disease (ischaemic heart disease and heart failure) in the China Kadoorie Biobank (CKB). His research work in CKB includes studies of the diagnostic accuracy, prognosis, treatment, risk prediction and evaluation of genetic and plasma biomarkers for stroke types and ischaemic heart disease and heart failure in CKB and related studies in the department and international consortia.
He was a member of the department's Strategic Oversight Committee, the International Steering Committee of CKB, Research Strategy and Management Committee of CKB and Co-chair of International Research Management Committee of CKB.
Plasma Proteomics to Identify Drug Targets for Ischemic Heart Disease.
Mazidi M. et al, (2023), J Am Coll Cardiol, 82, 1906 - 1920
MTHFR and risk of stroke and heart disease in a low-folate population: a prospective study of 156 000 Chinese adults.
Bennett DA. et al, (2023), Int J Epidemiol
Chronic hepatitis B virus infection and risk of stroke types: a prospective cohort study of 500,000 Chinese adults
CHEN Z. et al, (2023), Stroke
Minimal improvement in coronary artery disease risk prediction in Chinese population using polygenic risk scores: evidence from the China Kadoorie Biobank.
Yang S. et al, (2023), Chin Med J (Engl), 136, 2476 - 2483
Dietary amino acids and risk of stroke subtypes: a prospective analysis of 356,000 participants in seven European countries.
Tong TYN. et al, (2023), Eur J Nutr